Product Information
DROXIA 400 MG CAPSULE is a brand product labeled by H2-Pharma LLC, priced at $0.7817 per EA under NDC 61269040460. Its NADAC has been published 127 times since Apr 17, 2024.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
400 mg/1
Manufacturer
H2-Pharma LLCNDC
61269040460
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/17/2025
Active Ingredients
HYDROXYUREAApproval Type
New Drug (NDA)
FDA Application
NDA016295FDA Approved
Before 1982
TE Code
AB
On Market Since
6/1/2009
Pharmacological Classes
Price Statistics
The NADAC for DROXIA 400 MG CAPSULE has been published 127 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7817 per EA |
|---|---|
| All-time high | $0.7844 (Jul 16, 2025) |
| All-time low | $0.7767 (May 22, 2024) |
| 52-week high | $0.7817 |
| 52-week low | $0.7817 |
| Median price | $0.7817 |
| Average price | $0.7812 |
| Largest weekly change | -0.3% (Aug 20, 2025) |
| Weeks tracked | 127 |
| Tracking since | Apr 17, 2024 |
1W
N/A
1M
0.0%
3M
0.0%
6M
0.0%
1Y
0.0%
3Y
N/A
5Y
N/A
All
+0.4%
Last surveyed Sep 16, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the HYDROXYUREA market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
H2-Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
HYDROXYUREA market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimetabolite class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DROXIA 400 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for DROXIA 400 MG CAPSULE, manufactured by H2-Pharma LLC, is $0.7817 per EA (NDC 61269040460), effective Sep 16, 2026.
How has the price of DROXIA 400 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for DROXIA 400 MG CAPSULE has held within roughly two percent of its current level. It has been tracked across 127 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DROXIA 400 MG CAPSULE?
Since Apr 17, 2024, the NADAC for DROXIA 400 MG CAPSULE has ranged from a low of $0.7767 (May 22, 2024) to a high of $0.7844 (Jul 16, 2025), with a median of $0.7817 per EA.
Are there cheaper alternatives to DROXIA 400 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of DROXIA 400 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DROXIA 400 MG CAPSULE?
DROXIA 400 MG CAPSULE (NDC 61269040460) is labeled by H2-Pharma LLC, and CMS classifies it as a brand product.